OPKO Health, Inc. (TLV:OPK)
Israel
· Delayed Price · Currency is ILS · Price in ILA | Market Cap | 2.71B |
| Revenue (ttm) | 1.93B |
| Net Income (ttm) | -719.47M |
| Shares Out | n/a |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 291,636 |
| Average Volume | 293,727 |
| Open | 359.00 |
| Previous Close | 359.00 |
| Day's Range | 351.10 - 360.00 |
| 52-Week Range | 341.50 - 519.00 |
| Beta | 1.49 |
| RSI | 47.54 |
| Earnings Date | Apr 28, 2026 |
About OPKO Health
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst... [Read more]
Financial Performance
In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.
Financial numbers in USDNews
OPKO Health Earnings Call Transcript: Q1 2026
Q1 2026 saw progress in clinical pipeline, improved operating losses, and strong cash reserves. Diagnostics and pharma segments showed sequential and year-over-year improvements, with guidance reaffirmed for 2026. Partnerships and streamlined operations support future growth.
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first ...
OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financia...
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 202...
OPKO Health Earnings Call Transcript: Q4 2025
Q4 2025 revenue declined year-over-year due to asset sales, but diagnostics and pharma segments showed operational improvements, with 4Kscore and international sales driving growth. Strong cash position supports R&D and accelerated share repurchases.
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces fi...
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
This is the third program that s uccessfully combine s Entera's oral peptide N- Tab ® platform with OPKO 's advanced protein chemistry capabilities
OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company has restructured to focus on therapeutics, divesting diagnostics for profitability and advancing a robust pipeline through partnerships with Merck, Regeneron, and BARDA. Key assets include a Merck-partnered EBV vaccine, multi-specific antibodies, and a growing diagnostics business centered on the 4Kscore test.
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January...
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held Decemb...
OPKO Health Earnings Call Transcript: Q3 2025
Q3 2025 saw strong execution on strategic priorities, including the sale of oncology assets, robust cash position, and significant R&D progress. Diagnostics and pharma segments showed improved profitability, with BioReference and ModeX clinical programs advancing and new partnerships fueling future growth.
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights fro...
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U...
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
BURLINGTON, N.C. and MIAMI , Sept.
OPKO Health Earnings Call Transcript: Q2 2025
Q2 2025 saw improved operating losses and strong progress in streamlining diagnostics, with the pending oncology asset sale to Labcorp expected to boost profitability. Pharmaceutical R&D advanced, supported by BARDA funding and strategic partnerships, while a robust cash position and share repurchase program underpin capital allocation.
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second ...
NextPlat Issues Interim CEO Update Shareholder Letter
COCONUT GROVE, Fla. , June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technolo...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Mana...
OPKO Health Transcript: Jefferies Global Healthcare Conference 2025
Streamlined diagnostics with a major Labcorp sale, focusing on core profitability and growth. ModeX advances multispecific antibody and vaccine programs, with key clinical milestones and strong non-dilutive funding. Cash position is robust, supporting R&D and buybacks.
OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
Recent LabCorp transactions streamlined operations and improved profitability, while the pharmaceutical and diagnostics businesses are positioned for sustainable growth. Innovative R&D programs in immuno-oncology, obesity, and vaccines are advancing, with strong cash reserves and multiple catalysts expected in the next 12–18 months.
OPKO Health to Participate in Two Upcoming Investor Conferences
MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3 rd An...
OPKO Health Earnings Call Transcript: Q1 2025
Q1 2025 saw improved operating losses and a narrowed net loss, driven by cost reductions and the sale of BioReference's oncology business. Guidance for 2025 includes $675–$685 million in revenue, with continued investment in R&D and a focus on profitability post-transaction.
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock ...